PathologyWatch has filed a notice of an exempt offering of securities to raise $25,000,000.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, PathologyWatch is raising $25,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Daniel Lambert played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About PathologyWatch
PathologyWatch delivers an intuitive and easy-to-implement digital pathology solution for dermatologists. Our technology coupled with top tier dermatopathologists can streamline your clinical workflow, interfaces with your EMR of choice, and actually increase revenue, resulting in optimized clinical decision-making and patient care.
To learn more about PathologyWatch, visit http://pathologywatch.com/
Contact:
Daniel Lambert, Chief Executive Officer
877-463-5434
https://www.linkedin.com/in/dantlambert/
SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.